What Grann Pharmaceuticals does

Grann Pharmaceuticals Inc. is a privately held, pre-revenue biotechnology company headquartered in San Marcos, California, developing mRNA lipid nanoparticle (LNP) protein replacement therapies for diseases caused by single protein knockouts and mutations. The company's foundational technology combines mRNA payloads with proprietary lipid nanoparticles averaging 80 nanometers in size, engineered to cross the blood-brain barrier — a capability validated across multiple animal trials in several mouse species. This BBB-crossing delivery architecture underpins a pipeline of seven candidates: lead asset RTT-1 (Eleanor) for Rett Syndrome, GRN-1 for obesity and NAFLD, CA-1 for colorectal adenocarcinoma, DLG4-1, TCF4 PITT-1 for Pitt-Hopkins Syndrome, and GABRA1 and GABRG2 for GABA-A receptor variants.

The company was founded in September 2018 by Thomas Lyle Temple, inspired by his grandmother "Grannan" who passed from neuroblastoma. Its lead milestone was achieved on August 20, 2025, when Eleanor Elnekaveh became the first patient in the world to receive RTT-1, completing the regimen and reportedly regaining the ability to walk and communicate — a transition from proof of concept to treatment accomplished in 18 months. Operations are anchored at the California State University San Marcos Infinity Lab, with co-development support from Salus ASC and Combined Brain, and patient-community engagement via CURE GABA-A (founded by Monica Joanna Elnekaveh).

Grann Pharmaceuticals generates no current revenue. Its commercial model anticipates future one-time licensing of approved therapeutics, with current patient access routed through Single-Patient Expanded Access inquiries from families and treating physicians. The team comprises 1–10 employees led by CEO Thomas Lyle Temple, COO Patrick Granahan, and Business Development Manager River Danner. The company is actively preparing for FDA regulatory discussions to advance RTT-1 toward formal approval.

Name

Grann Pharmaceuticals

Legal name

Grann Pharmaceuticals Inc.

Website

https://grannpharma.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

Grann Pharmaceuticals is a pre-revenue, privately held biotech developing mRNA lipid nanoparticle protein replacement therapies for rare genetic diseases, with a lead program (RTT-1) dosed in the first Rett Syndrome patient in August 2025.

Ownership category

akta.pro rank

Product category

Rare Disease Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Non-viral Gene Delivery & Gene Therapy (LNP, polymers, electroporation, physical methods) (HLAAACAC)

akta.pro secondary industries

Gene Therapy for Rare/Monogenic Diseases (HLAAACAE), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Neurology/CNS Gene Therapies (HLAAACAH)

Keywords

• MRNA therapeutics
• Lipid nanoparticle delivery
• Protein replacement therapy
• Rare disease therapeutics
• Nucleic acid medicines

Headquarters

HQ city

San Marcos

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Therapeutic Development and Commercialization: Pre-revenue biotech company developing mRNA LNP-based therapeutics for rare diseases. Revenue will be generated through commercialized pharmaceutical products upon regulatory approval.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Grann Pharmaceuticals develops mRNA lipid nanoparticle (LNP) protein replacement therapies for rare diseases caused by single-protein knockouts and genetic mutations. Its lead investigational program, RTT-1 (codename "Eleanor"), targets Rett Syndrome, and the company maintains a pipeline of additional candidates spanning CNS disorders (DLG4, TCF4/Pitt-Hopkins, GABRA1, GABRG2), obesity/NAFLD (GRN-1), and colorectal adenocarcinoma (CA-1). The platform leverages an approximately 80 nm proprietary LNP engineered to cross the blood-brain barrier for intravenous delivery of functional protein-encoding mRNA.

Product overview

Grann Pharmaceuticals is a biotechnology company developing an mRNA lipid nanoparticle (LNP) platform for protein replacement therapies targeting diseases caused by single protein knockouts and mutations. The company's product portfolio consists of multiple pipeline candidates: RTT-1 (Eleanor) is the lead program (first patient dosed, treating Rett Syndrome); GRN-1 targets obesity and NAFLD; CA-1 targets colorectal adenocarcinoma; DLG4-1 targets DLG4; TCF4 PITT-1 targets Pitt-Hopkins Syndrome; and GABRA1 and GABRG2 target GABA-A receptor variants. The platform technology utilizes lipid nanoparticles (average size 80nm) engineered to cross the Blood-Brain Barrier for CNS delivery of mRNA payloads.

Differentiator

Problem solved

Functional benefit

Products and services

• RTT-1 (Eleanor)
• GRN-1
• CA-1
• DLG4-1
• TCF4 PITT-1
• GABRA1
• GABRG2

Quantifiable outcome

• 18 months from proof of concept to first patient treatment
• +2 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Four partnerships are on record, tiered core and minor.

• California State University San Marcos Infinity LabcoreStrategic or Co-development Partner · 20 August 2025Research partner instrumental in developing the RTT-1 (Eleanor) therapy. Provided laboratory facilities and scientific expertise supporting the breakthrough treatment. The Infinity Lab is a key research facility enabling Grann's mRNA LNP development work.
• Salus ASCminorStrategic or Co-development Partner · 20 August 2025Partner in the RTT-1 development and treatment process. Contributed to making the breakthrough possible for the first patient treatment.
• Combined BrainminorStrategic or Co-development Partner · 20 August 2025Consortium partner supporting rare disease research and development. Played a role in the RTT-1 (Eleanor) breakthrough.
• Elnekaveh FamilycoreOthers · 20 August 2025The family of Eleanor Elnekaveh (founding patient) who provided relentless advocacy and personal commitment to funding and advancing a path forward for RTT-1 treatment. Their personal mission to help Eleanor grew into the founding of Grann Pharmaceuticals' therapeutic program.

Scale indicators3 records

Recent moves1 record

Expansion highlights5 records

Direct peers

• BioNTech: BioNTech is a global mRNA therapeutics leader expanding beyond COVID-19 vaccines into oncology and rare disease protein-replacement candidates. Its LNP-mRNA platform overlaps directly with Grann's core technology.
• Moderna: Moderna is the leading mRNA therapeutics company with a broad pipeline spanning infectious disease vaccines, oncology, and rare diseases including protein-replacement programs. It is the most direct competitor to Grann's mRNA-LNP protein replacement platform and dwarfs it in scale and IP.
• Taysha Gene Therapies: Taysha is a clinical-stage gene therapy company focused on CNS and rare monogenic diseases using AAV delivery. It competes with Grann in the same rare-neurodevelopmental indication space (e.g., Rett Syndrome).
• Ultragenyx Pharmaceutical: Ultragenyx is a rare-disease biotech developing biologics and gene therapies for monogenic disorders including CNS targets (e.g., Angelman syndrome, OTC deficiency). It is one of the closest pure-play comparables in rare neurodevelopmental disease drug development.

Broad incumbents

• Ionis Pharmaceuticals: Ionis is an established antisense oligonucleotide (ASO) developer with multiple approved rare neurological disease drugs (e.g., Spinraza for SMA). It is a broad incumbent in CNS-accessible nucleic acid therapeutics and addresses several of the same monogenic CNS indications Grann targets.
• Vertex Pharmaceuticals: Vertex is a rare-disease specialty pharmaceutical company with a major cystic franchise and growing pipeline in monogenic diseases (e.g., CASGEVY for sickle cell). It is comparable to Grann as a strategic acquirer/partner for rare-disease protein-replacement assets.
• Alnylam Pharmaceuticals: Alnylam is a leading RNA-based therapeutics company (siRNA) treating rare genetic diseases. While its modality differs from mRNA LNP, it competes for the same rare-disease protein/RNA replacement opportunity and partnership capital.

Others

• Acuitas Therapeutics: Acuitas is a leading LNP technology developer whose ionizable lipid systems underpin Moderna's COVID-19 vaccine. It is comparable to Grann as a supplier/innovator of BBB-crossing and CNS-targeted LNP delivery technology.

Emerging players

• Design Therapeutics: Design Therapeutics is a clinical-stage biotech developing small-molecule gene-toggling therapies for serious genetic disorders including Friedreich ataxia and DM1. It overlaps with Grann's monogenic-disease protein-restoration thesis but uses a different modality.
• Shape Therapeutics: Shape Therapeutics is an RNA-focused biotech developing RNA-editing and AAV-delivered gene therapies for rare diseases, with explicit CNS targeting. It intersects with Grann's monogenic CNS protein-replacement strategy.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/grann-pharmaceuticals-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Grann Pharmaceuticals